FANJ
CTIC

Financial Architects (New Jersey)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Financial Architects (New Jersey)’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed – – 1607
2018
Q1 		$0 Hold
10
– – ﹤0.01% 1681
2017
Q4 		$0 Hold
10
– – ﹤0.01% 1683
2017
Q3 		$0 Hold
10
– – ﹤0.01% 1688
2017
Q2 		$0 Hold
10
– – ﹤0.01% 1725
2017
Q1 		$0 Buy
+10
New +$46 ﹤0.01% 1685
2016
Q4 		– Sell
-510
Closed -$2K – 1575
2016
Q3 		$2K Hold
510
– – ﹤0.01% 1383
2016
Q2 		$2K Buy
+510
New +$2.34K ﹤0.01% 1381

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Financial Architects (New Jersey)'s CTIC Position: Q2 2018 in Review

Financial Architects (New Jersey) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 10 shares.

Financial Architects (New Jersey) first reported a position in CTIC in Q2 2016 and held it in 7 quarters. The position peaked at $2K in Q3 2016. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

  • Financial Architects (New Jersey) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 10 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018.
  • Financial Architects (New Jersey) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2016 and held it in 7 quarters.
  • Financial Architects (New Jersey)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $2K in Q3 2016.
  • 83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2018, filed 3 Aug 2018.